With the dropping of the Avastin (bevacizumab) shoe last week - Genentech Inc. disclosed Phase III data showing the breast cancer drug missed its primary efficacy endpoint - came a renewed focus not only on vascular endothelial growth factor treatments but also on the disease itself. (BioWorld Financial Watch)

The climate may cool with September's advent, but the industry late last week was still expecting a blast of potentially hot autumnal news about Phase III trials of Genentech Inc.'s monoclonal antibody Avastin (bevacizumab) in combination with chemotherapy against breast cancer. (Bioworld Financial Watch)